01—Abstract
Summary
Summary of the 10-K filed February 20, 2025. Cited figures are marked; the original filing is the authoritative source.
Quest Diagnostics (DGX) closed 2024 with net revenues of $9.87 billiona, up 6.7% from $9.25 billion in 2023, and diluted EPS of $7.69, up 2.7%.
Growth was driven mainly by acquisitions, which contributed roughly 3.9 points to DIS revenue growth, and by a 1.3% increase in revenue per requisition. Organic requisition volume grew only 0.7%, and COVID-19 testing continued to decline, so the underlying base-business growth (DIS revenue up 9.0% including acquisitions, with requisitions up 6.2%) is meaningfully flattered by M&A. Operating income rose 6.7% to $1.35 billionb, but the operating margin was flat at 13.6% because cost of services and SG&A grew in line with revenue, and the company absorbed $127 million of intangible amortization and $62 million of restructuring and integration charges.
Management attributes roughly $1.24c of 2024 diluted EPS to these items on a net basis. The defining event of the year was the roughly $2.2 billion of acquisitions, most notably LifeLabs in Canada (about $1 billion, funded with an $1.85 billion senior notes offering) and a series of outreach lab purchases from hospital systems including Allina Health, OhioHealth and University Hospitals. Management targets acquisitions that add about 1-2% of revenue per year, so 2024 was well above that pace.
Free cash flow is thinner than the headline suggests: operating cash flow was $1.33 billiond against $425 million of capital expenditures, and total debt rose to about $6.2 billion. Leverage increased while the company stated a continued commitment to an investment-grade rating, and it raised its quarterly dividend 6.7% to $0.80 per share while repurchasing only $150 million of stock during the year. Investors should weigh the strategic growth in Advanced Diagnostics, the MRD and Alzheimer's testing pipeline, and cost programs such as Invigorate against several watch items disclosed in the filing.
These include PAMA Medicare reimbursement cuts, which Congress has delayed but which could resume in 2026, the FDA's phase-out of enforcement discretion for laboratory-developed tests, and a shift toward capitated payment arrangements, which rose to about 5% of revenue. The filing also notes a new multi-year "Project Nova" order-to-cash modernization program costing an estimated $250-310 million, and the risk of changes in federal healthcare policy following the 2024 U.S. presidential election.
02—Key points
Key Highlights
- Net revenues rose 6.7% to $9.87 billion, but roughly 3.9 points of DIS revenue growth came from acquisitions, and organic requisition volume grew only 0.7%.
- Diluted EPS increased 2.7% to $7.69, while operating margin held flat at 13.6% as cost of services and SG&A grew in line with revenue.
- Acquisitions totaling about $2.2 billion, led by LifeLabs (Canada, roughly $1 billion) and several hospital outreach lab purchases, drove the bulk of growth and added a material amount of goodwill and intangibles ($8.9 billion goodwill total).
- Total debt increased to about $6.2 billion after an $1.85 billion senior notes issuance, and operating cash flow of $1.33 billion covered capex of $425 million with limited room for large buybacks (only $150 million repurchased in 2024).
- The quarterly dividend was raised 6.7% to $0.80 per share, the 14th increase since 2012, and about $0.9 billion remains under the buyback authorization.
- Key regulatory risks include PAMA Medicare clinical lab fee cuts (delayed to January 2026 with a 15% annual cap), the FDA's phase-out of enforcement discretion for LDTs, and rising government and payer utilization controls.
- Management's Invigorate cost program targets about 3% annual savings, and the new multi-year Project Nova order-to-cash modernization is expected to cost $250-310 million through 2032.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2024, Quest Diagnostics Inc kept $0.09.
- Revenue$9.87B100.0%
- Cost of revenue−$6.63B67.1%
- Gross profit$3.24B32.9%
- Operating costs−$1.90B19.2%
- Operating income$1.35B13.6%
- Interest, other & tax−$475.0M4.8%
- Net income$871.0M8.8%
Where FY2024 revenue went
$9.87B- Cost of revenue: $6.63B, 67% of revenue
- SG&A: $1.77B, 18% of revenue
- Net income: $871.0M, 8.8% of revenue
- Other operating costs: $128.0M, 1.3% of revenue
- Interest, other & tax: $475.0M, 4.8% of revenue
Kept 8.8% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2024filed February 20, 2025Financial Statements
FY2024 against FY2023
| Line item | FY2024FY2023 | Change |
|---|---|---|
| Revenue | $9.87B$9.25B | +6.7% |
| Cost of Revenue | $6.63B$6.20B | +6.9% |
| Gross Profit | $3.24B$3.05B | +6.3% |
| SG&A Expenses | $1.77B$1.64B | +7.8% |
| Operating Expenses | $8.53B$7.99B | +6.7% |
| Operating Income | $1.35B$1.26B | +6.7% |
| Net Income | $871.00M$854.00M | +2.0% |
| EPS (Basic) | $7.78$7.59 | +2.5% |
| EPS (Diluted) | $7.69$7.49 | +2.7% |
| Shares Outstanding (Basic) | 111.00M112.00M | −0.9% |
| Shares Outstanding (Diluted) | 113.00M113.00M | 0.0% |
05—Questions
Frequently Asked Questions
How much of Quest's 2024 growth came from acquisitions versus the underlying business?
Acquisitions contributed about 3.9 percentage points of the 7.1% DIS revenue growth and about 4.8 points of the 5.5% requisition volume growth. Organic requisition volume grew just 0.7%, and COVID-19 testing declined, so most of the headline growth was acquired rather than organic.
Why did EPS grow only modestly despite revenue growth of nearly 7%?
Operating income rose only 6.7% in line with revenue, and interest expense increased 32% to $201 million from higher debt used to fund acquisitions. Amortization of intangibles also rose to $127 million, and 2024 results absorbed about $1.24 per diluted share of net items including amortization, restructuring and integration charges, and equity investment losses, which limited EPS growth to 2.7%.
Is Quest's balance sheet still in good shape after the acquisition spree?
Total debt rose to about $6.2 billion from $4.7 billion, and goodwill increased to $8.9 billion. Management says it remains committed to an investment-grade rating, has $1.3 billion of available credit facility capacity, and was in compliance with all financial covenants. Leverage is higher, however, and it limits flexibility for large buybacks.
What are the biggest policy risks to Quest's reimbursement?
The most significant is PAMA, which requires Medicare clinical lab fee schedule cuts. Congress has repeatedly delayed these cuts, and the filing notes reductions from 2026 to 2028 are capped at 15% annually. Further risks include government utilization controls such as prior authorization, growth in capitated payment arrangements, and the possible impact of changes in federal healthcare policy after the 2024 election.
Why is Quest investing in Advanced Diagnostics and what could it mean for growth?
Advanced Diagnostics includes molecular, oncology, and genetic testing, which carry higher reimbursement and faster growth than routine testing. Quest is expanding its Haystack MRD ctDNA test, its QUEST AD-DETECT Alzheimer's blood test portfolio, and next-generation sequencing. Gene-based and esoteric testing grew to 39% of net revenues in 2024 from 32% in 2022, and this mix shift supports future margin and growth potential, though the filing does not quantify expected returns.
06—Continue